Inflammatory mechanisms in Alzheimer disease: The role of beta-amyloid/glial interactions

Molecular Psychiatry

Volumn 2, Issue 2, 1997, Pages 91-95

  Pachter, J S ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; ANTIINFLAMMATORY AGENT; CHLOROQUINE; DEXAMETHASONE; INDOMETACIN;

ALZHEIMER DISEASE; ARTICLE; ASTROCYTE; CONTROLLED STUDY; GLIA CELL; HUMAN; HUMAN CELL; IMMUNE SYSTEM; INFLAMMATION; MICROGLIA; NERVE DEGENERATION; PRIORITY JOURNAL; SENILE PLAQUE;

EID: 0030898608     PISSN: 13594184     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.mp.4000212     Document Type: Article

References (58)

1. Aisen PS, Davis KL. Inflammatory mechanisms in Alzheimer's disease: implications for therapy. Am J Psychiatry 1994; 151: 1113.
2. Berkinbosch F, Biewenga J, Brouns M, Rozemuller JM, Strijbos P, van Dam A-M. Cytokines and inflammatory proteins in Alzheimer's disease. Res Immunol 1995; 143: 657-663.
3. McGeer PL, McGeer EG. The inflammatory response of brain: implications for therapy of Alzheimer and other neurodegenerative diseases. Brain Res Rev 1995; 21: 195-218.
4. Rogers J. Inflammation as a pathogenic mechanism in Alzheimer's disease. Arzneim-Forsch/Drug Res 1995; 45; 439-442.
5. Ishii T, Haga S, Shimuzu F. Identification of components of immunoglobulins in senile plaques by means of fluorescent antibody technique. Acta Neuropathol (Berl) 1975; 32: 157-162.
6. McRae A, Dahlstrom A. Cerebrospinal fluid antibodies: an indicator of immune responses in Alzheimer's diesease. Res Immunol 1992; 143: 663-667.
7. Alafuzoff I, Adolfsson R, Grunde-Iqbal I. Blood-brain barrier in Alzheimer dementia and in non-demented elderly. Acta Neuropathol (Berl) 1987; 73: 160-166.
8. Kalaria RN. The blood-brain barrier and cerebral microcirculation in Alzheimer disease. Cerebro Brain Metab Rev 1992; 4: 226-260.
9. Mattila KM, Pirttila T, Blennow K, Wallin A, Viitanen M, Frey H. Altered blood-brain barrier function in Alzheimer's disease? Acta Neurolog Scand 1994; 89: 192-198.
10. Abraham CR, Delkoe DJ, Potter H. Immunohistochemical identification of the serine protease inhibitor alpha-1 antichymotrypsin in the brain amyloid deposits of Alzheimer's disease. Cell 1988; 52: 487-501.
11. Bauer J, Strauss S, Schreiter-Gasser U, Ganter U, Schlegel P, Witt I, Yolk B, Berger M. Interleukin-6 and alpha-2-macroglobulin indicate an acute phase response in Alzheimer's disease cortices. FEBS Lett 1991; 285: 111-114.
12. Iwamoto N, Nishiyama E, Ohwada J, Arai H. Demonstration of CRP immunoreactivity in brains of Alzheimer's disease: immunohistochemical study using formic acid pretreatment of tissue sections. Neurosci Lett 1994; 177: 23-26.
13. Coria F, Castano E, Prelli F, Larrondo-Lillo M, van Duinen S, Shelanski ML, Frangione B. Isolation and characterization of amyloid P component from Alzheimer's disease and other types of cerebral amyloidosis. Lab Invest 1988; 58: 454-458.
14. Snow AD, Willmer J, Kisilevsky R. A close ultrastructural relationship between sulfated proteoglycans and AA amyloid fibrils. Lab Invest 1987; 57: 687-698.
15. Abbas AK, Lichtman AH, Pober JS. Cellular and Molecular Immunology. WB Saunders Co: Philadelphia, PA, 1991.
16. McGeer PL, McGeer EG. Complement proteins and complement inhibitors in Alzheimer's disease. Res Immunol 1992; 143: 621-624.
17. Eikenbloom P, Stam FC. Immunoglobulins and complement factors in senile plaques: an immunohistochemical study. Acta Neuropathol (Berl) 1982; 57: 239-242.
18. Ishii T, Haga S. Immuno-electron-microscopic localization of complements in amyloid fibrils of senile plaques. Acta Neuropathol (Berl) 1984; 63: 296-300.
19. McGeer PL, Akiyama H, Itagaki S, McGeer EG. Immune system response in Alzheimer's disease. Can J Neurol Sci 1989; 16: 516-527.
20. Akiyama H, McGeer PL. Brain microglia constitutively express β2 integrins. J Neuroimmunol 1990; 30: 81-93.
21. Akiyama H, Ikeda K, Kondo H, McGeer PL. Thrombin accumulation in brains of patients with Alzheimer's disease. Neurosci Lett 1992; 146: 152-154.
22. Kalaria RN, Golde T, Kroon SN, Perry G. Serine protease inhibitor antithrombin III and its messenger RNA in the pathogenesis of Alzheimer's disease. Am J Pathol 1993; 143: 886-893.
23. Yasuhara O, Walker DG, McGeer PL. Hageman factor and its binding sites are present in senile plaques of Alzheimer's disease. Brain Res 1994; 654: 234-240.
24. Mrak RE, Sheng JG, Griffin WST. Glial cytokines in Alzheimer's disease: review and pathogenic implications. Human Pathol 1995; 26: 816-823.
25. Benveniste EN. Astrocyte-microglia interactions. In: Murphy S (ed). Astrocytes Pharmacology and Function. Academic Press: New York, NY, 1993, pp 355-382.
26. Perry VH. Macrophages and the Nervous System. RG Landes Co: Austin, TX, 1994.
27. Griffin WST, Stanley LC, Ling C, White L, Macleod V, Perroth J, White CL, Araoz C. Brain interleukin-1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc Natl Acad Sci (USA) 1989; 86: 7611-7615.
28. Wood JA, Wood PL, Ryan R, Graff-Radford NR, Pilapil C, Robitaille Y, Quirion R. Cytokine indices in Alzheimer's temporal cortex: no changes in mature IL-1 beta or IL-1RA but increases in the associated acute phase proteins IL-6, alpha 2-macroglobulin and C-reactive protein. Brain Res 1993; 629: 245-252.
29. Cacabelos R, Alvarez XA, Fenandez-Novoa L, Franco A, Mangues R, Pellicer A, Nishimura T. Brain interleukin-1 beta in Alzheimer's disease and vascular dementia. Meth Find Exp Clin Pharmacol 1994; 16: 141-145.
30. Cacabelos R, Barquero M, Garcia P, Alvarez XA, Varela de Seijas E. Cerebrospinal fluid interleukin-1 beta (IL-1 beta) in Alzheimer's disease and neurological disorders. Meth Find Exp Clin Pharmacol 1991; 13: 455-458.
31. Griffin WST, Sheng JG, Roberts GW, Mrak RE. Interleukin-1 expression in different plaque types in Alzheimer's disease: significance in plaque evolution. J Neuropathol Exp Neurol 1995; 54: 276-281.
32. Dickson DW, Lee SC, Mattiace LA, Yen S-HC, Brosnan C. Microglia and cytokines in neurological disease, with special reference to AIDS and Alzheimer's disease. Glia 1993; 7: 75-83.
33. Frederickson RC. Astroglia in Alzheimer's disease. Neurobiol aging 1992; 13: 239-253.
34. Banati RB, Gehrmann J, Schubert P, Kreutzberg GW. Cytotoxicity of microglia. Glia 1993; 7: 111-118.
35. Eddleston M, Mucke L. Molecular profile of reactive astrocytes - implications for their role in neurologic disease. Neuroscience 1993; 54: 15-36.
36. Stanley LC, Mrak RE, Woody RC, Perrot LJ, Zhang S-X, Marshak DR, Nelson SJ, Griffin WST. Glial cytokines as neuropathogenic factors in HIV infection: pathogenic similarities to Alzheimer's disease. J Neuropathol Exp Neurol 1994; 53: 231-238.
37. Adams DO, Hamilton TA. Molecular basis of macrophage activation. In: Lewis CE, McGee JO (eds). The Macrophage. IRL: Oxford, 1992, pp 75-114.
38. Klegeris A, Walker DG, McGeer PL. Activation of macrophages by Alzheimer β amyloid peptide. Biochem Biophys Res Comm 1994; 199: 984-990.
39. Meda L, Cassatella MA, Szendrei GI, Otvos L Jr, Baron P, Villalba M, Ferrari D, Rossi F. Activation of microglial cells by β-amyloid protein and interferon-γ. Nature 1995; 374: 647-650.
40. Davis JB, McMurray HF, Schubert D. The amyloid beta-protein of Alzheimer's disease is chemotactic for mononuclear phagocytes. Biochem Biophys Res Comm 1992; 189: 1096-1100.
41. Araujo MD, Cotman CW. β-Amyloid stimulates glial cells in vitro to produce growth factors that accumulate in senile plaques in Alzheimer's disease. Brain Res 1992; 569: 141-145.
42. Fagarasan M, Aisen PS. IL-1 and anti-inflammatory drugs modulate Aβ cytotoxicity in PC12 cells. Brain Res 1996; 723: 231-234.
43. Lee SC, Dickson DW, Liu W, Brosnan CF. Induction of nitric oxide synthase activity in human astrocytes by interleukin-1 beta and interferon-gamma. J Neuroimmunol 1993; 46: 19-24.
44. London JA, Biegel D, Pachter JS. Neurocytopathic effects of β-amyloid-stimulated monocytes: a potential mechanism for central nervous system damage in Alzheimer disease. Proc Natl Acad Sci USA 1996; 93: 4147-4152.
45. Giulian D, Haverkamp LJ, Li J, Karshin WL, Yu J, Tom D, Li X, Kirkpatrick JB. Senile plaques stimulate microglia to release a neurotoxin found in Alzheimer brain. Neurochem Int 1995; 27: 119-137.
46. Wisniewski HM, Barcikowska M, Kida E. Phagocytosis of β/A4 amyloid fibrils of the neuritic neocortical plaques. Acta Neuropathol 1991; 81: 588-590.
47. Frautschy SA, Cole GM, Baird A. Phagocytosis and deposition of vascular β-amyloid in rat brains injected with Alzheimer β-amyloid. Am J Pathol 1992; 140: 1389-1399.
48. Frackowiak J, Wisniewski HM, Wegiel J, Merz GS, Iqbal K, Wang KC. Ultrastructure of the microglia that phagocytose amyloid and the microglia that produce β-amyloid fibrils. Acta Neuropathol 1992; 84: 225-233.
49. Shaffer LM, Dority MD, Gupta-Bansal R, Frederickson RCA, Younkin SG, Brunden KR. Amyloid β protein (Aβ) removal by neuroglial cells in culture. Neurobiol Aging 1995; 16: 737-745.
50. Chao CC, Hu S, Sheng WS, Bu D, Bukrinsky MI, Peterson PK. Cytokine-stimulated astrocytes damage human neurons via a nitric oxide mechanism. Glia 1996; 16: 276-284.
51. Lassman H, Zimprich F, Vass K, Hickey WF. Microglial cells are a component of the perivascular limitans. J Neurosci Res 1991; 28: 236-243.
52. Brugg B, Dubreuil YL, Huber G, Wollman EE, Delhaye-Bouchard N, Mariani J. Inflammatory processes induce beta-amyloid precursor protein changes in mouse brain. Proc Natl Acad Sci USA 1995; 92: 3032-3035.
53. McGeer PL, Schulzer M, McGeer EG. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. Neurology 1996; 47: 425-432.
54. Breitner JCS, Gau BA, Welsh KA, Plassman BL, McDonald WM, Helms MJ, Anthony JC. Inverse association of anti-inflammatory treatments and Alzheimer's disease: initial results of a co-twin control study. Neurology 1994; 44: 227-232.
55. Rogers J, Kirby LC, Hempelman SR, Berry DL, McGeer PL, Kasniak AW, Zalinski J, Cofield M, Mansukhani L, Wilson P, Kogan F. Clinical trial of indomethacin in Alzheimer's disease. Neurology 1993; 43: 1609-1611.
56. Ferriera SH, Vane JR. New aspects of the mode of action of nonsteroid anti-inflammatory drugs. A Rev Pharmac 1974; 14: 57-73.
57. Giulian D, Robertson C. Inhibition of mononuclear phagocytes reduces ischemic injury in the spinal cord. Ann Neurol 1990; 27: 33-42.
58. Chao CC, Molitor TW, Hu S. Neuroprotective role of IL-4 against activated microglia. J Immunol 1993; 151: 1473-1481.